Evicenter
MarkdownMedical informationP&T meetings
Claseprubart (DNTH103)

Generalized myasthenia gravis

Launch
Not announced
Last updated
120 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatment

Heterogeneity of treatment effect

9 evidence topics · 9 sources

Inebilizumab effect by antibody status
Week 26 outcomeOverall populationAnti-AChR antibody positiveAnti-MuSK antibody positive
MG-ADL difference from placebo“-1.9”“-1.8”“-2.2”
MG-ADL p-value“<0.0001”“0.0015”“0.0297”
QMG difference from placebo“-2.5”“-2.5”“-2.3”
QMG p-value“0.0002”“0.0011”“NS”